key: cord-0932115-zfvb79j3
authors: Paules, Catharine I; Gallagher, Shannon K; Rapaka, Rekha R; Davey, Richard T; Doernberg, Sarah B; Grossberg, Robert; Hynes, Noreen A; Ponce, Philip; Short, William R; Voell, Jocelyn; Wang, Jing; Yang, Otto O; Wolfe, Cameron R; Lye, David C; Dodd, Lori E; Benson, Constance A
title: Remdesivir for the prevention of invasive mechanical ventilation or death in COVID-19 - A post-hoc analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data
date: 2021-08-11
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab695
sha: a764f992bc9e80bdb9abd669a9d50fcd24c2d8fe
doc_id: 932115
cord_uid: zfvb79j3

This post-hoc analysis of The Adaptive COVID-19 Treatment Trial-1 shows a treatment effect of remdesivir on progression to invasive mechanical ventilation (IMV) or death. Additionally, we create a risk profile that better predicts progression than baseline oxygen requirement alone. The highest risk group derives the greatest treatment effect from RDV.

M a n u s c r i p t 4

The Adaptive COVID-19 Treatment Trial (ACTT-1) identified remdesivir (RDV) as the first antiviral to benefit hospitalized COVID-19 patients, demonstrating a significant improvement in median time to recovery from 15 days with placebo to 10 days with RDV 1 . On post-hoc subgroup analysis using an eight-point ordinal scale, the largest benefit of RDV was seen in subjects receiving supplemental oxygen at baseline, with no clear benefit in other subgroups.

ACTT-1 was not designed to evaluate RDV's impact on progression to invasive mechanical ventilation (IMV) or death. Though deaths were numerically lower in the RDV arm, the difference was not statistically significant. Here, we retrospectively explore RDV's treatment effect within the dataset as a whole and by defining a new risk profile for disease progression, not solely dependent upon baseline oxygen requirement.

Dataset: ACTT-1 included 1062 subjects; 1051 had an ordinal score (OS) recorded. OS reflected the subject's oxygen requirement at enrollment; OS4, not requiring supplemental oxygen; OS5, requiring supplemental oxygen; OS6, requiring non-invasive positive pressure ventilation (NIPPV) or high-flow oxygen (HFO); OS7, requiring IMV or extracorporeal membrane oxygenation (ECMO). Time to progression to IMV or death was defined as number of days until first occurrence of IMV or death, except for subjects requiring IMV at baseline, where the endpoint was time until death.

Demographic characteristics, biomarkers, comorbidities, and temporal features were collected, as previously described 1 . Missing biomarker values, for those missing fewer than 5%, were imputed as the in-group median within OS. Supplemental Sections 2-3.

We developed a risk profile for progression to IMV or death by examining thirteen features in addition to baseline oxygen requirement. Features were selected using the results of a model fit on A c c e p t e d M a n u s c r i p t 5 half the placebo arm data. The risk profile was developed from the selected features on the remaining placebo recipients. We grouped participants into risk profile quartiles: "high," "moderate," "lower," and "least" risk. We compared risk profile and OS accuracy using leave-oneout cross-validated area under the receiver operating characteristic curve (AUC) 2 in placebo recipients 2 . We fit separate Fine-Gray competing risk 3 (time to recovery vs. progression to IMV/death) and logistic regression (binary day 29 outcomes) models to evaluate RDV efficacy within each quartile(not adjusted for multiplicity). Supplemental Sections 4-7.

The risk profile included four baseline variables: 1) platelet count, 2) absolute lymphocyte count (ALC), 3) absolute neutrophil count (ANC) and 4) oxygen requirement. Independently, lower platelet count, lower ALC, and higher ANC were associated with greater risk of progression to IMV or death (Table 1) . Each risk quartile included participants with a range of baseline oxygen requirements. For example, in the "high risk" quartile 34.0% (89/262) required IMV/ECMO, 18.7% (49/262) required NIPPV or HFO, 38.2% (100/262) required supplemental oxygen, and 9.2% (24/262) required no supplemental oxygen.

Observed proportions of patients progressing to IMV or death by quartile were 37.4% (98/262) "high risk", 26.2% (69/263) "moderate risk", 16.7% (44/263)"lower risk", and 8.3% (22/263) "least risk".

The risk profile AUC was higher than OS alone (0.73 vs 0.53; p<0.0001), better predicting progression to IMV or death (supplemental figure 5.1). In this regard, the "high risk" quartile captured more deaths than OS7: 45.6% (62/136) vs 41.9% (57/136) all deaths, respectively. When compared to OS7, the "high risk" quartile had lower median baseline ALC (0.6 x 10^9/L versus 0.9 x 10^9/L), A c c e p t e d M a n u s c r i p t 6 (69/94) of OS4 and OS5 subjects that progressed to IMV or death were captured in either the "high risk" or "moderate risk" quartiles (supplemental table 5.3).

Treatment with RDV was associated with fewer progressions to IMV or death across the entire cohort (hazard ratio 0.67; [95% CI: 0.52, 0.87] p=0.0023), as well as in OS5 (hazard ratio 0.45; [95% CI: 0.29, 0.71] p=0.0003). The "high risk" quartile also showed a significant RDV treatment effect (hazard ratio 0.59; [95% CI: 0.39, 0.87] p=0.009). (Figure 1 )

The risk quartiles were also assessed for time to one-point OS improvement, time to recovery (ACTT-1 endpoint), and death. Statistically significant effects for RDV treatment in the "high risk" quartile were observed for time to one-point improvement and time to recovery, with no impact seen in any of the other risk quartiles (Supplemental table 6.1 and supplemental figure 6.1).

In the ACTT-1 cohort, combining baseline ALC, ANC, and platelets with baseline OS resulted in a more predictive risk profile of participant outcome. Low platelet count, low ALC, and high ANC have been shown to correlate with worsening disease severity in small cohorts of patients with COVID-19 4-6 . Low ALC, in particular, has been linked to increased mortality 7 . By incorporating these commonly measured hematologic parameters, we improved the predicted risk of IMV or death beyond OS alone. Although our risk profile requires validation in large prospective studies, it lends credence to the hypothesis that OS groups are heterogeneous and that some patients within each OS are more likely to experience severe outcomes.

Our results highlight a need to reassess treatment guidelines regarding the use of RDV in Patients in this "high risk" quartile, whose baseline oxygen requirements ranged from room air to IMV, receiving RDV had a hazard ratio of 0.59 [95% 0.39, 0.87], p=0.009 for IMV or death compared to patients receiving placebo. It should be noted that the extensive clinical and laboratory characterizations intrinsic to the ACTT-1 study design afforded the in-depth analyses described. This type of granularity may be needed to capture the presence of a RDV treatment effect if present in only a subgroup of participants.

Our study has several limitations. First, this is a post-hoc analysis with an endpoint, time to progression to IMV or death, which differed from the primary endpoint for ACTT-1, time to recovery.

Progression to IMV or death was chosen because it is a clinically meaningful endpoint being used increasingly in other trials. We used time-to-event models instead of binary outcome models, to Second, several key baseline variables were not available, including body mass index, inflammatory markers, and viral load (the latter two assessments are planned). The inclusion of these variables may influence the risk profile. Third, in baseline OS7 patients only one step in disease progression to the worst outcome, death, is possible while, in all risk profile quartiles, the worst outcome is either IMV or death. However, when assessing death alone the risk profile AUC was also higher than that of M a n u s c r i p t 12 

Remdesivir for the Treatment of Covid-19 -Final Report

Semiparametric Regression for the Area Under the Receiver Operating Characteristic Curve

Practical recommendations for reporting Fine-Gray model analyses for competing risk data

The prognostic value of general laboratory testing in patients with COVID-19

A neutrophil activation signature predicts critical illness and mortality in COVID-19

Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study

Lymphopenia as a Biological Predictor of Outcomes in COVID-19 Patients: A Nationwide Cohort Study

World Health Organization. COVID-19 Clinical management: living guidance

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

COVID-19) Treatment Guidelines

Society of Critical Care Medicine Surviving Sepsis Campaign. COVID-19 Guidelines

A c c e p t e d M a n u s c r i p t 11 A c c e p t e d M a n u s c r i p t Probability of progression to IMV or death is shown in Panel C for subjects receiving RDV (blue) and placebo (red) in the overall ACTT-1 dataset. HR estimates with a value < 1 indicate that treatment effect is associated with being less likely to progress to IMV or death. Number-at-risk table is provided for each plot with numbers colored by treatment group.A c c e p t e d M a n u s c r i p t